article · International Journal of Contemporary Pediatrics
Background: The concept of prediction of neonatal hyperbilirubinemia offers an attractive option in identifying babies at risk of significant hyperbilirubinemia. This study determined the ability of the cord bilirubin/albumin ratio to predict significant hyperbilirubinemia. Methods: This was a hospital-based longitudinal cross-sectional study conducted on four hundred and seventy-one neonates in a southwest community in Nigeria. Blood samples were obtained for cord bilirubin, cord albumin and cord bilirubin/albumin ratio were analyzed for their predictive ability of significant hyperbilirubinemia at 72-96 hours with follow-up. Receiver observation curve analysis (ROC) was employed to compare the predictive abilities of cord bilirubin, cord albumin and cord bilirubin/albumin ratio. Results: The prevalence of significant hyperbilirubinemia was 4.2%. Cord bilirubin and cord bilirubin/albumin ratio were found to have a significant relationship with the development of significant hyperbilirubinemia at 48-72 hours follow-up. Cord bilirubin of greater than 1.58 mg/dl was shown to be predictive of significant hyperbilirubinemia with a sensitivity, specificity, negative predictive value, and positive predictive value of 70%, 48.34%, 5.7% and 97.3% respectively. Conclusions: Comparing the predictive abilities of cord bilirubin, cord albumin and cord bilirubin/albumin ratio; the study reveals that cord bilirubin has the best ability to predict significant hyperbilirubinemia.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.18203/2349-3291.ijcp20242009
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.